+734.5%
QBTS vs MRNA
+159.5%
+574.9%
-83.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.9% | +1.3% | -6.2% | -5.1% |
| 7D | -25.7% | -13.8% | -11.9% | -24.3% |
| 30D | -37.9% | -17.7% | -20.3% | -36.4% |
| 3M | -62.2% | +14.3% | -76.5% | -62.9% |
| 6M | -59.8% | +336.0% | -395.8% | -72.5% |
| YTD | -72.0% | +575.9% | -648.0% | -84.3% |
| 1Y | -68.8% | +724.4% | -793.2% | -83.8% |
| All | +734.5% | +159.5% | +574.9% | +342.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling